Eagle Asset Management Inc Cytokinetics Inc Transaction History

Eagle Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$63.75 - $108.06 $516,247 - $875,069	-8,098 Reduced 3.98%	195,449 $13.7 Million
Q4 2023 Feb 12, 2024	SELL	$26.88 - $83.49 $5.19 Million - $16.1 Million	-193,223 Reduced 48.7%	203,547 $17 Million
Q3 2023 Nov 13, 2023	SELL	$29.46 - $36.61 $217,768 - $270,621	-7,392 Reduced 1.83%	396,770 $11.7 Million
Q2 2023 Aug 09, 2023	SELL	$32.62 - $40.75 $3.14 Million - $3.92 Million	-96,223 Reduced 19.23%	404,162 $13.2 Million
Q1 2023 May 08, 2023	SELL	$33.36 - $45.71 $1.59 Million - $2.18 Million	-47,692 Reduced 8.7%	500,385 $17.6 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $381,773 - $545,497	-10,673 Reduced 1.91%	548,077 $25.1 Million
Q3 2022 Nov 07, 2022	BUY	$38.54 - $54.52 $4.91 Million - $6.94 Million	127,327 Added 29.51%	558,750 $27.1 Million
Q2 2022 Aug 10, 2022	BUY	$33.93 - $48.92 $6.68 Million - $9.63 Million	196,878 Added 83.94%	431,423 $17 Million
Q1 2022 May 12, 2022	BUY	$29.74 - $46.0 $6.98 Million - $10.8 Million	234,545 New	234,545 $8.63 Million

409

125M

4.6M

2.43M

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.6B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.